Sign up to save your podcasts
Or
Share Ghassan Abou-Alfa, MD, MBA - Renovating the Clinical Rulebook for HCC: Multidirectional Management With Innovative Immunotherapy and Targeted Platforms
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ghassan Abou-Alfa, MD, MBA - Renovating the Clinical Rulebook for HCC: Multidirectional Management With Innovative Immunotherapy and Targeted Platforms
Go online to PeerView.com/UUY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Approaches to managing patients with hepatocellular carcinoma (HCC) are undergoing renovation! A recent wave of improved therapeutic regimens, including immunotherapy/anti-VEGF combinations (eg, atezolizumab and bevacizumab), dual immunotherapy combinations (ie, durvalumab-tremelimumab), and next-generation TKIs (ie, lenvatinib) has been introduced in the upfront setting. Recent additions to the second-line setting have delivered improved options for patients with HCC including immune checkpoint inhibitors (eg, pembrolizumab and tislelizumab) and multikinase inhibitors (ie, cabozantinib and regorafenib). Emerging data on other up-and-coming targeted platforms are forthcoming, including evidence for perioperative applications in earlier disease settings. With all of these developments, how should we update our clinical rulebooks for treating HCC? This activity, based on a recent live symposium, uncovers innovative treatment strategies in early and intermediate HCC and presents validated and emerging strategies in advanced HCC. The unique Tumor Board format uses case-based scenarios to facilitate an interactive discussion covering practical guidance you can use to renovate your own clinical rulebook. Upon completion of this activity, participants should be better able to: Examine the latest clinical evidence supporting the use of immunotherapy, targeted therapy, and combination regimens for the management of HCC; Integrate individualized treatment plans for patients with HCC based on the latest clinical evidence, expert recommendations, and patient-specific factors; and Employ team-based strategies and practical considerations when integrating novel HCC regimens, including monitoring, patient consultation, and adverse event management
View all episodes
By PVI, PeerView Institute for Medical Education
4.3
99 ratings
Go online to PeerView.com/UUY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Approaches to managing patients with hepatocellular carcinoma (HCC) are undergoing renovation! A recent wave of improved therapeutic regimens, including immunotherapy/anti-VEGF combinations (eg, atezolizumab and bevacizumab), dual immunotherapy combinations (ie, durvalumab-tremelimumab), and next-generation TKIs (ie, lenvatinib) has been introduced in the upfront setting. Recent additions to the second-line setting have delivered improved options for patients with HCC including immune checkpoint inhibitors (eg, pembrolizumab and tislelizumab) and multikinase inhibitors (ie, cabozantinib and regorafenib). Emerging data on other up-and-coming targeted platforms are forthcoming, including evidence for perioperative applications in earlier disease settings. With all of these developments, how should we update our clinical rulebooks for treating HCC? This activity, based on a recent live symposium, uncovers innovative treatment strategies in early and intermediate HCC and presents validated and emerging strategies in advanced HCC. The unique Tumor Board format uses case-based scenarios to facilitate an interactive discussion covering practical guidance you can use to renovate your own clinical rulebook. Upon completion of this activity, participants should be better able to: Examine the latest clinical evidence supporting the use of immunotherapy, targeted therapy, and combination regimens for the management of HCC; Integrate individualized treatment plans for patients with HCC based on the latest clinical evidence, expert recommendations, and patient-specific factors; and Employ team-based strategies and practical considerations when integrating novel HCC regimens, including monitoring, patient consultation, and adverse event management
More shows like PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
View all
JAMA Editors' Summary
129 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
6 Listeners
Lung Cancer Update
31 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
10 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
28 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
9 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
3 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
5 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
NEJM This Week
315 Listeners
Journal of Clinical Oncology (JCO) Podcast
42 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
Research To Practice | Oncology Videos
115 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners
JAMA Clinical Reviews
482 Listeners
ASCO Daily News
54 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
21 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
323 Listeners
Oncology Today with Dr Neil Love
53 Listeners
CCO Oncology Podcast
9 Listeners
Two Onc Docs
166 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
38 Listeners